Neurology®
The most widely read and highly cited peer-reviewed Neurology journal
Quick Search
Advanced Search
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
 Volume 59, Number 4, August 27, 2002
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Malm, H.
Right arrow Articles by Somer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Malm, H.
Right arrow Articles by Somer, M.
Related Collections
Right arrow All Pediatric
Right arrow Developmental disorders
Right arrow Antiepileptic drugs

Neurology 2002;59:630-633
© 2002 American Academy of Neurology
Brief Communications

Valproate embryopathy in three sets of siblings: Further proof of hereditary susceptibility

H. Malm, MD, E. Kajantie, MD, S. Kivirikko, MD PhD, H. Kääriäinen, MD PhD, M. Peippo, MD and M. Somer, MD PhD

From the Teratology Information Service, Department of Medical Genetics (Dr. Malm), Department of Medical Genetics (Drs. Kääriäinen and Peippo), Family Federation of Finland; Department of Clinical Pharmacology (Dr. Malm), Hospital for Children and Adolescents (Dr. Kajantie); and Department of Medical Genetics (Drs Kajantie, Kivirikko, and Somer), Helsinki University Central Hospital, Helsinki, Finland.

Address correspondence and reprint requests to Dr. Heli Malm, Teratology Information, Department of Medical Genetics, Family Federation of Finland, P.O. Box 849, Helsinki, FIN-00101, Finland.

The fetal valproate syndrome (FVS) is characterized by distinctive facial appearance, major and minor malformations, and developmental delay. Generally, only a small proportion of prenatally exposed children are affected. The authors describe three families in whom the occurrence of FVS in all the siblings strongly suggests hereditary susceptibility to valproic acid-induced adverse outcome. The risk for recurrence in a subsequent pregnancy may be high and should be taken into account in the counseling of parents and in considering drug treatment.




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
M D O'Brien and S K Gilmour-White
Management of epilepsy in women
Postgrad. Med. J., May 1, 2005; 81(955): 278 - 285.
[Abstract] [Full Text] [PDF]